Demand for GLP-1 drugs isn’t going away anytime soon — and the healthcare system will continue to feel the economic impact, according to a new report.
The consultancy’s Health Research Institute noted that healthcare spending is likely to reach its highest level in 13 years.
Pfizer will move forward a once-daily formulation of its GLP-1 drug danuglipron based on promising new data.
While most patients experienced 5% weight loss or greater, those who took Zepbound experienced the greatest benefit.
A study found that patients who took GLP-1 drugs saw a significant reduction in the risk of certain cancers, including esophageal, endometrial, liver and kidney cancer.
Havas said the internal consultancy service will focus on responses to disruptive drugs like GLP-1s.
The 90-second hero spot highlights the results of a 68-week clinical study.
The long-running comedy show released South Park: The End of Obesity, a special on Paramount+ skewering the weight-loss drug craze.
Novo’s trial represents the promise of potential label expansion that Ozempic and other GLP-1 drugs could have beyond treating diabetes and obesity.
The first report from IRIS, the latest intelligence offering from Real Chemistry, delves into the power of GLP-1 influencers.
Get the most out of
Register for free and enjoy unlimited access to: